Bristol-Myers Squibb Co. (BMY)

Statement of Cash Flows

Difficulty: Beginner

The cash flow statement provides information about a company’s cash receipts and cash payments during an accounting period, showing how these cash flaws link the ending cash balance to the beginning balance shown on the company’s statement of financial position.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Bristol-Myers Squibb Co., Consolidated Statement of Cash Flows

USD $ in millions

	12 months ended	Dec 31, 2018		Dec 31, 2017		Dec 31, 2016		Dec 31, 2015		Dec 31, 2014
	Net earnings
	Depreciation and amortization, net
	Deferred income taxes
	Stock-based compensation
	Impairment charges
	Pension settlements and amortization
	Divestiture gains and royalties
	Asset acquisition charges
	(Gain) loss on equity investments
	Other adjustments
	Receivables
	Inventories
	Accounts payable
	Deferred income
	Income taxes payable
	Other
	Changes in operating assets and liabilities
	Adjustments to reconcile net earnings to net cash provided by operating activities
	Net cash provided by operating activities
	Sale and maturities of marketable securities
	Purchase of marketable securities
	Capital expenditures
	Divestiture and other proceeds
	Acquisition and other payments
	Net cash (used in) provided by investing activities
	Short-term debt obligations, net
	Issuance of long-term debt
	Repayment of long-term debt
	Repurchase of common stock
	Dividends
	Other
	Net cash used in financing activities
	Effect of exchange rates on cash and cash equivalents
	Increase (decrease) in cash and cash equivalents
	Cash and cash equivalents at beginning of year
	Cash and cash equivalents at end of year

Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).

Item	Description	The company
Net cash provided by operating activities	Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.	Bristol-Myers Squibb Co.’s net cash provided by operating activities increased from 2016 to 2017 and from 2017 to 2018.
Net cash (used in) provided by investing activities	Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.	Bristol-Myers Squibb Co.’s net cash (used in) provided by investing activities declined from 2016 to 2017 and from 2017 to 2018.
Net cash used in financing activities	Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.	Bristol-Myers Squibb Co.’s net cash used in financing activities declined from 2016 to 2017 but then slightly increased from 2017 to 2018.

	Bristol-Myers Squibb Co.	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

	All companies
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality